HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 20, No 12, December 2016 – Medical Imaging Technology       » Climate Change Could Hurt Coffee, Help Banana Production       » Partnerships and Innovation: Shaping the Future of Healthcare in Asia Pacific       » Chugai's Novel Antibody Technologies Put Singapore at the Centre of Fight Against Disease       » NUS Scientists Discover the "Switch" that Makes Breast Cancer Cells Aggressive      
BIOBOARD - JAPAN
Eisai signs agreement with Epizyme and Roche Molecular Systems to develop companion diagnostic
Eisai Co., Ltd. signed an agreement with Epizyme, Inc. and Roche Molecular Systems Inc. to collaborate on the development of a companion diagnostic to help Eisai and Epizyme identify patients for their research on lymphomas. Specifically, the new companion diagnostic will further enable Eisai and Epizyme to advance personalized therapeutics for patients with lymphomas possessing genetic mutations in the epigenetic enzyme EZH2.

Since April 2011, Eisai has collaborated with Epizyme under a strategic partnership agreement focused on the development of cancer therapies that target EZH2 and been engaging in research aimed at the creation of such therapies. As demonstrated in a recent study conducted by Epizyme, an EZH2 inhibitor has been shown to eradicate lymphoma cells possessing change-of-function mutation in EZH2. The results of this study suggest that EZH2 is a driving oncogene in these cancers and therefore an important therapeutic target.

In parallel with the clinical development of this EZH2 inhibitor, Eisai and Epizyme are working with RMS, a company with strengths in the development and commercialization of companion diagnostics, to develop a companion diagnostic to identify a genetically defined subset of patients with lymphoma to proceed with effective clinical development.

Remarkable progress has been made in recent years in the field of oncology regarding genetics research. By maximizing full utilization of internal and external information obtained from cutting-edge research in human biology, including a drug creation approach based in genetics and epigenetics, Eisai will continue to contribute to advances in personalized therapeutics for patients with cancer.

Click here for the complete issue.

NEWS CRUNCH  
news Accuron Technologies' MedTech Division Invests into AWAK Technologies
news Philips introduces PerformanceBridge suite of operational performance improvement software and services for radiology departments
news Give a Gift that Will Last a Lifetime this Holiday Season with Smile Train
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Lungs & Respiratory System
February:
Cancer Research, Treatment/Technology
March:
Traditional Chinese Medicines
April:
Eye Care/ Eye Health
May:
The Piece of Your Mind - Brain Health/Science
June:
Featuring Biotech Start-Ups/Companies
July:
Food Science & Technology
August:
Diabetics Technology
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy